Home World News Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast... World News Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... July 6, 2023 Foodie Fridays: It’s Cucumber Season! July 23, 2021 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... October 1, 2024 FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 Load more HOT NEWS Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... New option to treat advanced oesophageal cancer approved for NHS in... Mohs Surgery for Skin Cancer: What to Know and What to... Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of...
